Skip to content

Prime Medicine PRME Contract Liabilities

Contract Liabilities at other companies

Regenxbio logo
RegenxbioRGNX
$22.78M-13.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$136.35M-58.0%
Wave Life Sciences logo
Wave Life SciencesWVE
$14.6M+161%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$2.13M+390%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's contract liabilities?
Prime Medicine (PRME) reported contract liabilities of $57.78M in Q1 2026.
How has Prime Medicine's contract liabilities changed year-over-year?
Prime Medicine's contract liabilities decreased by 4.8% year-over-year, from $60.66M to $57.78M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.